Jason Sheehan: The role of angiogenesis inhibitors on glioblastoma management – OncoDaily
Jason Sheehan: The role of angiogenesis inhibitors on glioblastoma management / Ali Mohammad Mokhtari, Ali Mortezaei, Ali Motamed-Sanaye, Amir Afshari, Amir
Related Articles
Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC
Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.
Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT
Orca-T was retrospectively associated with improved OS in patients with high-risk hematologic malignancies undergoing allogeneic stem cell transplant.
Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC
The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.
ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
Bishal Gyawali: Looking back, 2024 was an excellent year – OncoDaily
Bishal Gyawali: Looking back, 2024 was an excellent year / Abhenil Mittal, Abhinav Komanduri, Aditya Arkalgud, Alessandro Hammond, Arman Reza Chowdhury,
FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC
The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
Great Debates and Updates in TNBC – Uniting Global Experts at BGICC 2025 – OncoDaily
Great Debates and Updates in TNBC – Uniting Global Experts at BGICC 2025 / BGICC, BGICC 2025, Breast Gynecological and Immunooncology International Cancer
